Pharmaceuticals
China Diabetes Drugs Market Analysis
The China diabetes drugs market size was valued at $4.96 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $8.9 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The China diabetes drug market will grow because China is the country with the largest population of people with diabetes in the world. The key market players are Gan & Lee Pharmaceuticals (CHN), Tonghua Dongbao Pharmaceutical (CHN), Jiangsu Hengrui Medicine (CHN), and others.
Buy Now
China Diabetes Drugs Market Executive Summary
The China diabetes drugs market size was valued at $4.96 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $8.9 Bn in 2030. China's healthcare expenditure has been steadily increasing in recent years. According to the National Bureau of Statistics of China, healthcare expenditure in China reached $1.3 trillion in 2020, accounting for 6.9% of the country's GDP. This represents a significant increase from just 4.7% of GDP in 2009. One of the main factors driving the increase in healthcare expenditure in China is the aging population. With an increasing number of elderly people in the country, there is greater demand for healthcare services and higher healthcare costs. In addition, the government has been increasing its investment in healthcare, with a focus on improving access to healthcare services and increasing health insurance coverage.
According to the International Diabetes Federation (IDF), China has the largest number of people with diabetes in the world, with an estimated 116 Mn adults aged 20-79 years living with the disease in 2021. The prevalence of diabetes in China is also increasing rapidly due to changing lifestyles, urbanization, and an aging population.
The high prevalence of diabetes in China has led to significant demand for diabetes drugs in the country. The diabetes drug market in China is expected to grow rapidly in the coming years, driven by the increasing prevalence of diabetes and the government's efforts to improve healthcare access and affordability. The Chinese government has taken several steps to address the diabetes epidemic in the country, including launching a national diabetes prevention and treatment program and implementing policies to promote healthy lifestyles and prevent diabetes-related complications.
In addition, multinational pharmaceutical companies have also been increasing their presence in the Chinese market and developing new diabetes drugs to meet the growing demand. Local pharmaceutical companies have also been investing in research and development to develop innovative diabetes treatments. The high prevalence of diabetes in China has had a significant impact on the diabetes drug market in the country, leading to increased demand for diabetes drugs and investment in research and development by both local and multinational pharmaceutical companies.
Market Dynamics
Market Growth Drivers Analysis
China is the country with the largest population of people with diabetes in the world, which has led to significant demand for diabetes drugs in the country. The diabetes drugs market in China is expected to grow rapidly in the coming years, driven by several factors.
One of the main drivers of the diabetes drugs market in China is the increasing prevalence of diabetes. This is due to changing lifestyles, urbanization, and an aging population, all of which have contributed to the rise in diabetes cases in the country. As a result, there is a growing demand for diabetes drugs in China, which is driving the growth of the market.
Another driver of the diabetes drugs market in China is the government's efforts to improve healthcare access and affordability. The Chinese government has launched a national diabetes prevention and treatment program and implemented policies to promote healthy lifestyles and prevent diabetes-related complications. This has led to an increased focus on diabetes care in the country, which is driving the demand for diabetes drugs.
Market Restraints
One of the main factors is the high cost of diabetes drugs. Many patients in China may not be able to afford the cost of diabetes drugs, which can limit the growth of the market. In addition, there are concerns about the safety and efficacy of some diabetes drugs, which can also impact the growth of the market.
Another factor that may restrain the growth of the diabetes drugs market in China is the uneven distribution of healthcare resources. While healthcare services in urban areas are generally better developed and more accessible, there are still significant disparities in healthcare access and quality between urban and rural areas. This can limit the growth of the diabetes drugs market in rural areas, where there may be less demand for diabetes drugs.
Competitive Landscape
Key Players
- Gan & Lee Pharmaceuticals (CHN)
- Tonghua Dongbao Pharmaceutical (CHN)
- Jiangsu Hengrui Medicine (CHN)
- Humanwell Healthcare Group (CHN)
- Shanghai Fosun Pharmaceutical Group (CHN)
- Sanofi
- Johnson & Johnson
- Abott
- Bayer Pharmaceuticals
- Novo Nordisk
- Merck
- Eli Lilly and Company
- AstraZeneca
- Boehringer Ingelheim
- Novartis
- GlaxoSmithKline
Notable deals
February 2021: Novo Nordisk announced a collaboration with BeiGene to develop and commercialize a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of diabetes and other metabolic disorders in China. The two companies will work together on the development, manufacturing, and commercialization of the drug.
March 2021: Hua Medicine and Eli Lilly and Company announced a strategic collaboration to develop and commercialize novel diabetes treatments in China. The collaboration will focus on the development of Hua Medicine's lead drug candidate, dorzagliatin, which is a dual-acting glucokinase activator (GKA) that has shown promising results in clinical trials.
August 2021: Jiangsu Hengrui Medicine announced a partnership with Hikma Pharmaceuticals to develop and commercialize insulin products in the Middle East and North Africa region. The partnership includes the manufacturing and supply of insulin products by Jiangsu Hengrui Medicine and the commercialization and distribution of the products by Hikma Pharmaceuticals.
Healthcare Policies and Regulatory Landscape
Policy changes and Reimbursement scenario
The regulation of diabetes drugs in China is overseen by the China National Medical Products Administration (NMPA), which is responsible for the approval and registration of all pharmaceutical products in the country. In order for a diabetes drug to be approved for use in China, it must undergo rigorous clinical trials and meet the safety and efficacy standards set by the NMPA.
Diabetes drugs in China are typically covered by the country's National Health Insurance Program, which provides coverage for a wide range of healthcare services and products, including prescription medications. However, the reimbursement rate for diabetes drugs in China can vary depending on a number of factors, such as the drug's cost, its effectiveness, and the patient's individual circumstances.
In 2019, the government announced plans to reduce the prices of 36 commonly used diabetes drugs by an average of 60%. Additionally, the government has also introduced policies aimed at promoting the use of generic diabetes drugs, which are typically less expensive than brand-name drugs. For example, in 2020, the government issued guidelines requiring hospitals to prioritize the use of generic drugs in their procurement processes.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Diabetes Drugs Market Segmentation
By Drug Type (Revenue, USD Bn):
The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :
- Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
- Exenatide (Byetta)
- Dulaglutide (Trulicity)
- Semaglutide (Ozempic, Wegovy)
- Liraglutide (`Saxenda, Victoza)
- Lixisenatide (Adlyxin)
- Pramlintide (Symlin)
- Tirzepatide (Mounjaro)
- Albiglutide (Tanzeum)
- Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)
By Application (Revenue, USD Bn):
Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.
- Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
- Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
- Other diabetes types
By Distribution Channel (Revenue, USD Bn):
Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Insights10 will provide you with the reports within 10 key parameters which are:
- Market Overview
- Market Growth Drivers & Restraints
- Epidemiology of Disease Type
- Market Segmentation
- Market Share
- Competitive Landscape
- Key Company Profiles
- Healthcare Policies & Regulatory Framework
- Reimbursement Scenario
- Factors Driving Future Growth
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
(1).png)
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
- Establishing market drivers and trends
- Analyzing the regulatory landscape to understand future growth
- Market Segment based analysis to obtain revenue/volume
- Analyzing current needs and determining penetration to estimate the market
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
- Intelligent insights to take informed business decisions
- Qualitative, acute and result oriented market analysis
- Market size and forecasts from 2022 to 2030
- Opportunities for expansion and in-depth market analysis
- Segmentation and regional revenue forecasts
- Analysis of the market share and competitive landscape
- Strategic Recommendations to chart future course of action
- Comprehensive Market Research Report in PDF and PPT formats
Need more?
- Ask our analyst how this study was put together to learn more
- Discuss additional requirements as part of the free customisation
- Add more countries or regions to the scope
- Get answers to specific business questions
- Develop the business case to launch the product
- Find out how this report may influence your business revenue
Related reports (by category)
Pharmaceuticals
Qatar HIV Therapeutics Market Analysis
Pharmaceuticals
Vietnam Pharmaceutical Solvent Market Analysis
Pharmaceuticals
Vietnam Psoriasis Drugs Market Analysis
Related reports (by geography)
Healthcare Services
China Healthcare Insurance Market Analysis
Pharmaceuticals
China Oral Anti-Diabetes Drugs Market Analysis
Healthcare Services
